Kaiyuan Zhu

Kaiyuan Zhu

Auto-generated profile, based on publicly available information

Kaiyuan Zhu

City University of Hong Kong Shenzhen Research Institute, Shenzhen, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2014 in Autophagy
Verified
Journal Article
Open access
YLYingying Lu
Yingying Lu
SDShichen Dong
Shichen Dong
BHBaixia Hao
Baixia Hao
CLChang Li
Chang Li
KZKaiyuan Zhu
Kaiyuan Zhu
JYJianbo Yue
Jianbo Yue
Autophagy is a catabolic lysosomal degradation process essential for cellular homeostasis and cell survival. Dysfunctional autophagy has been associated with a wide range of human diseases, e.g., cancer and neurodegenerative diseases. A large number of small molecules that modulate autophagy have been widely used to dissect this process and some of them, e.g., chloroquine (CQ), might be ultimately applied to treat a variety of autophagy-associated human diseases. Here we found that vacuolin-1 potently and reversibly inhibited the fusion between autophagosomes and lysosomes in mammalian cells, thereby inducing the accumulation of autophagosomes. Interestingly, vacuolin-1 was less toxic but at least 10-fold more potent in inhibiting autophagy compared with CQ. Vacuolin-1 treatment also blocked the fusion between endosomes and lysosomes, resulting in a defect in general endosomal-lysosomal degradation. Treatment of cells with vacuolin-1 alkalinized lysosomal pH and decreased lysosomal Ca2+ content. Besides m...

23 December 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KZKehui Zhang
Kehui Zhang
WSWei Sun
Wei Sun
LHLihong Huang
Lihong Huang
KZKaiyuan Zhu
Kaiyuan Zhu
FPFen Pei
Fen Pei
JYJianbo Yue
Jianbo Yue

16 April 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
KZKaiyuan Zhu
Kaiyuan Zhu
YCYang Cai
Yang Cai
XSXiaotong Si
Xiaotong Si
ZYZuodong Ye
Zuodong Ye
YGYuanzhu Gao
Yuanzhu Gao
JYJianbo Yue
Jianbo Yue

17 February 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
XSXianli Shi
Xianli Shi
KZKaiyuan Zhu
Kaiyuan Zhu
ZYZuodong Ye
Zuodong Ye
JYJianbo Yue
Jianbo Yue
One of the critical regulatory mechanisms for cell cycle progression is the timely degradation of CDK inhibitors, including p21 Cip1 and p27 Kip1 . VCP/p97, an AAA‐ATPase, is reported to be overexpressed in many types of cancers. Here, we found that treatment of MCF‐7 human breast cancer cells with DBeQ, a VCP inhibitor, or VCP knockdown in MCF‐7 cells arrested cells at G1 phase, accompanied with the blockage of both p21 and p27 degradation. Whereas, double knockdown of p21 and p2 7 in MCF‐7 cells rendered cells refractory to DBeQ‐induced G1 arrest. Moreover, inhibition or knockdown of VCP or UFD1 , one of VCP's co‐factors, in MCF‐7, NIH3T3, or HEK293T cells blocked the nuclear export of p27 during earlier G1 phase after mitogen stimulation. We also identified the nuclear localization sequence (NLS) of VCP, and found that adding back wild‐type VCP, not the NLS‐deleted VCP mutant, restored the nuclear export and degradation of p27 in VCP knockout MCF‐7 cells. Importantly, we found that VCP inhibition sensitized breast cancer cells to the treatment of several anticancer therapeutics both in vitro and in vivo . Taken together, our study not only uncovers the mechanisms underlying VCP‐mediated cell proliferation control but also provides potential therapeutic option for cancer treatment.

22 May 2020 in FASEB BioAdvances
Verified
Journal Article
Open access
PDF file
KZKaiyuan Zhu
Kaiyuan Zhu
JYJianbo Yue
Jianbo Yue
AYAndrew Yen
Andrew Yen
The known collaboration between all‐transretinoic acid and interferon motivates this study of the dependence of RA‐induced leukemic cell differentiation on interferon regulatory factor‐1 (IRF‐1), a transcription factor that is the main mediator of interferon effects. In the HL‐60 acute myeloid leukemia (AML) model that represents a rare RA‐responsive subtype of AML, IRF‐1 is not expressed until RA induces its prominent expression, and ectopic IRF‐1 expression enhances RA‐induced differentiation, motivating interest in how IRF‐1 is putatively needed for RA response. Accordingly, we created CRISPR/Cas9‐mediated IRF‐1 knockout HL‐60 cells. Contrary to expectation, loss of IRF‐1 did not diminish RA‐induced cellular signaling that propels differentiation, and RA‐induced cell differentiation markers, including CD38 and CD11b expression and G1/G0cell cycle arrest, were unaffected. However, elimination of IRF‐1 inhibited RA‐induced p47phox expression and inducible oxidative metabolism detected by reactive oxygen species (ROS), suggesting IRF‐1 is essential for mature granulocytic inducible oxidative metabolism. In the case of 1,25‐Dihydroxyvitamin D3‐induced differentiation to monocytes, IRF‐1 loss did not affect D3‐induced expression of CD38, CD11b, and CD14, and G1/0 arrest; but inhibited ROS production. Our data suggest that IRF‐1 is inessential for differentiation but upregulates p47phox expression for mature‐cell ROS production.